← Back to Screener
Canton Strategic Holdings, Inc. Common Stock (CNTN)
Price$3.49
Favorite Metrics
Price vs S&P 500 (26W)8.59%
Price vs S&P 500 (4W)-3.68%
Market Capitalization$202.83M
All Metrics
Cash Flow / Share (Quarterly)$-2.52
Price vs S&P 500 (YTD)15.51%
EPS (TTM)$-2.89
10-Day Avg Trading Volume0.72M
EPS Excl Extra (TTM)$-2.89
EPS (Annual)$-1.12
ROI (Annual)-9.03%
Cash / Share (Quarterly)$0.46
ROA (Last FY)-6.92%
EBITD / Share (TTM)$-3.85
Cash Flow / Share (Annual)$-2.52
P/B Ratio0.51x
Net Income / Employee (Annual)$-18
Net Interest Coverage (TTM)-4.33x
ROA (TTM)-27.05%
EPS Incl Extra (Annual)$-1.12
Current Ratio (Annual)157.97x
Quick Ratio (Quarterly)157.86x
3-Month Avg Trading Volume0.77M
52-Week Price Return204.81%
Revenue / Employee (TTM)$0
52-Week High$9.08
EPS Excl Extra (Annual)$-1.12
26-Week Price Return12.58%
Quick Ratio (Annual)157.86x
13-Week Price Return18.94%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)157.97x
Revenue / Employee (Annual)$0
Cash / Share (Annual)$0.46
3-Month Return Std Dev102.79%
Net Income / Employee (TTM)$-18
ROE (Last FY)-9.03%
Net Interest Coverage (Annual)-322.02x
EPS Basic Excl Extra (Annual)$-1.12
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-2.89
ROI (TTM)-24.73%
Revenue / Share (Annual)$0.00
Price vs S&P 500 (52W)174.98%
Year-to-Date Return18.15%
5-Day Price Return5.29%
EPS Normalized (Annual)$-1.12
ROA (5Y Avg)-180.25%
Month-to-Date Return9.48%
EBITD / Share (Annual)$-1.31
LT Debt / Equity (Annual)0.00x
LT Debt / Equity (Quarterly)0.00x
EPS Basic Excl Extra (TTM)$-2.89
Price vs S&P 500 (13W)18.25%
Beta1.64x
Revenue / Share (TTM)$0.00
ROE (TTM)-24.76%
52-Week Low$1.05
Analyst Recommendations
Sep 2025
Oct 2025
Nov 2025
Dec 2025
4.14
4.14
4.14
4.14
Industry Peers — Pharmaceuticals(309)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
CNTNCanton Strategic Holdings, Inc. Common Stock | — | — | — | — | $3.49 |
LLYEli Lilly & Co. | 13.08x | 44.70% | 83.04% | 27.59% | $903.99 |
JNJJohnson & Johnson | 5.94x | 7.87% | 67.95% | 14.90% | $234.54 |
ABBVABBVIE INC. | 6.04x | 8.57% | 71.62% | -2.88% | $208.99 |
MRKMerck & Co., Inc. | 4.41x | 1.31% | 78.55% | 21.23% | $115.46 |
AZNAstraZeneca PLC | 5.28x | 8.63% | 81.31% | 21.88% | $200.47 |
NVSNovartis AG | 4.98x | 8.91% | 75.82% | 15.26% | $149.73 |
NVONovo-Nordisk A/S | 3.62x | 6.43% | 80.98% | 20.66% | $40.93 |
ABTAbbott Laboratories | 3.66x | 6.59% | 56.50% | 8.20% | $95.47 |
PFEPfizer Inc. | 2.47x | -1.64% | 75.81% | -3.51% | $27.22 |
BMYBristol-Myers Squibb Co. | 2.47x | -0.22% | 72.63% | — | $58.96 |
About
Canton Strategic Holdings Inc operates two distinct business segments: a blockchain infrastructure business centered on the Canton Network, where it runs a validator node and facilitates financial market digitization through Canton Coin, and a clinical-stage biotech company developing therapeutics for neurological and respiratory disorders. The biotech division's lead candidate, GV104, is in clinical development for respiratory and nervous system depression in military personnel and first responders, with plans to expand into additional indications. The pipeline includes GV023 for autoimmune diseases and an early-stage multispecific biologic platform.